Company intelligence / Profile preview

AAN

Ownership: Private
Employees: ~20
Development stage: Other

Overview

AAN is a South Korean biotechnology company specializing in the development of small molecule therapeutics for neurodegenerative diseases. The company leverages a proprietary platform focused on autophagy induction to promote the clearance of toxic protein aggregates, such as amyloid-beta and alpha-synuclein, which are central to the pathogenesis of Alzheimer's and Parkinson's diseases. Its lead candidate, AAN-001, is currently in clinical development for Alzheimer's disease, while AAN-002 is being advanced for Parkinson's disease. AAN's approach aims to provide disease-modifying treatments by restoring cellular protein homeostasis and preventing neurodegeneration.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Daegu Gyeongbuk Institute of Science and Technology (DGIST)

Beyond the preview

Go deeper on AAN.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AAN.

Explore the full profile